Pharma & Biotech

While Eli Lilly continues to generate headlines and record earnings with its blockbuster weight-loss drugs, the pharmaceutical giant's leadership is...

Following the failure of its lead clinical candidate, Quince Therapeutics has initiated a formal review of its strategic options. The...

Investor attention turns to Vanda Pharmaceuticals today as the company prepares to release its fourth-quarter and full-year 2025 financial statements...

AIM ImmunoTech has initiated a critical financing effort to support its ongoing clinical programs. The biotechnology firm announced the commencement...

The corporate evolution from Diffusion Pharmaceuticals to its successor, CervoMed, is now complete. This strategic shift moves the company's valuation...

A notable new institutional position has been disclosed in medical device firm enVVeno Medical. Recent regulatory filings reveal that Braeden...

The corporate dissolution of the former 23andMe Holding Co. is entering its final stage. A decisive legal milestone was reached...

The biotechnology firm Enzo Biochem has completed its departure from public markets. The company's shares have been delisted following its...

As of February 2026, the two biotech pioneers synonymous with the mRNA-based COVID-19 vaccine rollout, Moderna and BioNTech, face a...

Eli Lilly & Company is currently benefiting from two significant and concurrent developments that bolster its business outlook. These events...